N-terminally PEGylated human interferon-β-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model

Bioconjugate Chemistry

Volumn 17, Issue 1, 2006, Pages 179-188

  Baker, Darren P ^a   Lin, Edward Y ^a   Lin, KoChung ^a   Pellegrini, Maria ^a   Petter, Russell C ^a   Chen, Ling Ling ^a   Arduini, Robert M ^a   Brickelmaier, Margot ^a   Wen, Dingyi ^a   Hess, Donna M ^a   Chen, Liqing ^a   Grant, Donna ^a   Whitty, Adrian ^a   Gill, Alan ^a   Lindner, Daniel J ^b   Pepinsky, R Blake ^a  

^a BIOGEN   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGY; GLYCOPROTEINS; MAMMALS; ONCOLOGY; PHARMACOKINETICS; PROTEINS; VIRUSES;

% REDUCTIONS; COMPARISON STUDY; DOSE COMPARISON; IN-VIVO; PEGYLATED; PEGYLATED PROTEINS; PHARMACOKINETIC PROPERTIES; SINGLE-DOSE; VESSEL NUMBER; VIVO EFFICACIES;

BLOOD VESSELS;

BETA INTERFERON; BETA1A INTERFERON; CYTOKINE; INTERFERON BETA SERINE; MACROGOL DERIVATIVE; METHOXYPOLY(ETHYLENE GLYCOL) O 2 METHYLPROPIONALDEHYDE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PEGINTERFERON BETA 1A; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; MELANOMA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUDE MOUSE; RAT; TUMOR VASCULARIZATION;

ANIMALIA; HEPATITIS C VIRUS; MUS MUSCULUS;

EID: 31544475726     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc050237q     Document Type: Article

References (52)

1. Sen, G., and Lengyel, P. (1992) The Interferon System: a Bird's Eye View of Its Biochemistry. J. Biol. Chem. 267, 5017-5020.
2. Tyring, S. K. (1995) Interferons: Biochemistry and Mechanisms of Action. Am. J. Obstet. Gynecol. 172.
3. Peters, M. (1996) Actions of Cytokines on the Immune Response and Viral Interactions: an Overview. Hepatology 23, 909-916.
4. Uze, G., Lutfalla, G., and Mogensen, K. E. (1995) α and β Interferons and their Receptors and their Friends and Relations. J. Interferon Cytokine Res. 15, 3-26.
5. Cohen, B., Novick, D., Barak, S., and Rubinstein, M. (1995) Ligand-induced Association of the Type I Interferon Receptor Components. Mol. Cell Biol. 15, 4208-4214.
6. Piehler, J., and Schreiber, G. (1999) Biophysical Analysis of the Interaction of Human Ifnar2 Expressed in E.coli with IFNα2. J. Mol. Biol. 289, 57-67.
7. Arduini, R. M., Strauch, K. L., Runkel, L. A., Carlson, M. M., Hronowski, X., Foley, S. F., Young, C. N., Cheng, W., Hochman, P. S., and Baker, D. P. (1999) Characterization of a Soluble Ternary Complex Formed Between Human Interferon-β-1a and its Receptor Chains. Protein Science 8, 1867-1877.
8. Velazquez, L., Fellous, M., Stark, G. R., and Pellegrini, S. (1992) A Protein Tyrosine Kinase in the Interferon α/β Signaling Pathway. Cell 70, 313-322.
9. tyk2, an Interferon-α-activated Tyrosine Kinase, is Physically Associated with an Interferon-α Receptor. J. Biol. Chem. 269, 3518-3522.
10. tyk2 Tyrosine Kinase. Mol. Cell. Biol. 14, 8133-8142.
11. Novick, D., Cohen, B., and Rubinstein, M. (1994) The Human Interferon α/β Receptor: Characterization and Molecular Cloning. Cell 77, 391-400.
12. Yang, C.-H., Shi, W., Basu, L., Murti, A., Constantinescu, S. N., Blatte, L., Croze, E., Mullersman, J. E., and Pfeffer, L. M. (1996) Direct Association of STAT3 with the IFNAR-1 Chain of the Human Type I Interferon Receptor. J. Biol. Chem. 271, 8057-8061.
13. Li, X., Leung, S., Kerr, I. M., and Stark, G. R. (1997) Functional Subdomains of STAT2 Required for Preassociation with the Alpha Interferon Receptor and for Signaling. Mol. Cell. Biol. 17, 2048-2056.
14. Darnell, J. E., Kerr, I. M., and Stark, G. R. (1994) Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins. Science 264, 1415-1421.
15. Marler, J. J., Rubin, J. B., Trede, N. S., Connors, S., Grier, H., Upton, J., Mulliken, J. B., and Folkman, J. (2002) Successful Antiangiogenic Therapy of Giant Cell Angioblastoma with Interferon Alfa 2b: Report of 2 Cases. Pediatrics 109, E37.
16. Orchard, P. J., Smith, C. M., Woods, W. G., Day, D. L., Dehner, L. P., and Shapiro, R. (1989) Treatment of Haemangioendotheliomas with Alpha Interferon. Lancet 2, 565-567.
17. Ezekowitz, R. A. B., Mulliken, J. B., and Folkman, J. (1992) Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of Infancy. N. Eng. J. Med. 326, 1456-1463.
18. Kozlowski, A., Charles, S. A., and Harris, J. M. (2001) Development of Pegylated Interferons for the Treatment of Chronic Hepatitis C. Biodrugs 15, 419-429.
19. Baker, D. E. (2001) Pegylated Interferons. Rev. Gastroenterol. Disord. 1, 87-99.
20. Harris, J. M., and Chess, R. B. (2003) Effect of Pegylation on Pharmaceuticals. Nature Rev. 2, 214-221.
21. Glue, P., Fang, J. W. S., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S. K., Salfi, M., Jacobs, S., and the Hepatitis C Intervention Therapy Group (2000) Pegylated Interferon-α2b: Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy Data. Clin. Pharmacol. Ther. 68, 556-567.
22. Lindsay, K. L., Trepo, C., Heintges, T., Shiffman, M. L., Gordon, S. C., Hoefs, J. C., Schiff, E. R., Goodman, Z. D., Laughlin, M., Yao, R., Albrecht, J. K., for the Hepatitis Interventional Therapy Group (2001) A Randomized, Double-Blind Trial Comparing Pegylated Interferon Alfa-2b to Interferon Alfa-2b as Initial Treatment for Chronic Hepatitis C. Hepatology 34, 395-403.
23. Manns, M. P., McHutchinson, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M. L., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., Albrecht, J. K., and the International Hepatitis Interventional Therapy Group (2001) Peginterferon Alfa-2b Plus Ribavirin Compared with Interferon Alfa-2b Plus Ribavirin for the Initial Treatment of Chronic Hepatitis C: a Randomized Trial. Lancet 358, 958-965.
24. Reddy, K. R., Modi, M. W., and Pedder, S. (2002) Use of Peginterferon alfa-2a (40 KD) (Pegasys) for the Treatment of Hepatitis C. Adv. Drug Delivery Rev. 54, 571-586.
25. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M.-Y., Gane, E., O'Grady, J., Reichen, J., Diago, M., Lin, A., Hoffman, J., and Brunda, M. J. (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C. N. Eng. J. Med. 343, 1666-1672.
26. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G. E., Dusheiko, G. M., Lee, S. S., Balart, L., Reindollar, R., Reddy, R. K., Wright, T. L., Lin, A., Hoffman, J., and de Pamphilis, J. (2000) Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis. N. Eng. J. Med. 343, 1673-1680.
27. Fried, M. W., Shiffman, M. L., Reddy, R. K., Smith, C., Marinos, G., Goncales, F. L., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., and Yu, J. (2002) Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. N. Eng. J. Med. 347, 975-982.
28. Crawford, J. (2002) Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. Drugs 62, 89-98.
29. Li, D. K. B., Paty, D. W., and the UBC MS/MRI Analysis Research Group and the PRISMS Study Group (1999) Magnetic Resonace Imaging Results of the PRISMS Trial: A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. Ann. Neurol. 46, 197-206.
30. The IFNβ Multiple Sclerosis Study Group (1993) Interferon Beta-1b is Effective in Relapsing-Remitting Multiple Sclerosis. I. Clinical Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Neurology 43, 655-661.
31. Habersetzer, F., Boyer, N., Marcellin, P., Bailly, F., Ahmed, S. N., Alam, J. J., Benhamou, J. P., and Trepo, C. (2000) A Pilot Study of Recombinant Interferon Beta-1a for the Treatment of Chronic Hepatitis C. Liver 20, 437-441.
32. Barbaro, G., Di Lorenzo, G., Soldini, M., Giancaspro, G., Pellicelli, A., Grisorio, B., and Barbarini, G. (1999) Intravenous Recombinant Interferon-Beta versus Interferon-Alpha-2b and Ribavirin in Combination for Short-Term Treatment of Chronic Hepatitis C Patients not Responding to Interferon-Alpha. Scand. J. Gastroenterol. 34, 928-933.
33. Kakizaki, S., Tagaki, H., Yamada, T., Ichikawa, T., Abe, T., Sohara, N., Kosone, T., Kaneko, M., Takezawa, J., Takayama, H., Nagamine, T., and Mori, M. (1999) Evaluation of Twice-Daily Administration of Interferon-Beta for Chronic Hepatitis C. J. Viral Hepatol. 6, 315-319.
34. Yoshioka, K., Yano, M., Hirofuji, H., Arao, M., Kusakabe, A., Sameshima, Y., Kuriki, J., Kurowaka, S., Murase, K., Ishikawa, T., and Kakumu, S. (2000) Randomized Controlled Trial of Twice-a-Day Administration of Natural Interferon Beta for Chronic Hepatitis C. Hepatol. Res. 18, 310-319.
35. Kaito, M., Yasui-Kawamura, N., Iwasa, M., Kobayashi, Y., Nakagawa, N., Fujita, N., Ikoma, J., Gabazza, E. C., Watanabe, S., and Adachi, Y. (2003) Twice-a-Day Versus Once-a-Day Interferon-Beta Therapy in Chronic Hepatitis C. Hepatogastroenterology 50, 775-778.
36. Festi, D., Sandri, L., Mazzella, G., Roda, E., Sacco, T., Staniscia, T., Capodisca, S., Vestito, A., and Colecchia, A. (2004) Safety of Interferon Beta Treatment for Chronic HCV Hepatitis. World J. Gastroenterol. 10, 12-16.
37. Runkel, L. A., deDios, C., Karpusas, M., Betzenhauser, M., Muldowney, C., Zafari, M., Benjamin, C. D., Miller, S., Hochman, P. S., and Whitty, A. (2000) Systematic Mutational Mapping of Sites on Human Interferon-β-1a that are Important for Receptor Binding and Functional Activity. Biochemistry 39, 2538-2551.
38. Runkel, L., Meier, W., Pepinsky, R. B., Karpusas, M., Whitty, A., Kimball, K., Brickelmaier, M., Muldowney, C., Jones, W., and Goelz, S. E. (1998) Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon-β (IFN-β). Pharm. Res. 15, 641-649.
39. Pepinsky, R. B., Lepage, D. J., Gill, A., Chakraborty, A., Vaidyanathan, S., Green, M., Baker, D. P., Whalley, E., Hochman, P. S., and Martin, P. (2001) Improved Pharmacokinetic Properties of a Polyethylene Glycol-Modified Form of Interferon-β-1a with Preserved In Vitro Bioactivity. J. Pharmacol. Exp. Ther. 297, 1059-1066.
40. Gill, S. C., and von Hippel, P. H. (1989) Calculation of Protein Extinction Coefficients from Amino Acid Sequence Data. Anal. Biochem. 182, 319-326.
41. Lindner, D. J., and Borden, E. C. (1997) Effects of Tamoxifen and Interferon-β or the Combination on Tumor-Induced Angiogenesis. Int. J. Cancer 71, 456-461.
42. Bauer, J. A., Morrison, B. H., Grane, R. W., Jacobs, B, S., Borden, E. C., and Lindner, J. (2003) IFN-α2b and Thalidomide Synergistically Inhibit Tumor-Induced Angiogenesis. J. Interferon Cytokine Res. 23, 3-10.
43. Arduini, R. M., Li, Z., Rapoza, A., Gronke, R., Hess, D. M., Wen, D., Miatkowski, K., Coots, C., Kaffashan, A., Viseux, N., Delaney, J., Domon, B., Young, C. N., Boynton, R., Chen, L. L., Chen, L., Betzenhauser, M., Miller, S., Gill, A., Pepinsky, R. B., Hochman, P. S., and Baker, D. P. (2004) Expression, Purification, and Characterization of Rat Interferon-β, and Preparation of an N-Terminally PEGylated Form with Improved Pharmacokinetic Parameters. Protein Expression Purification 34, 229-242.
44. Mager, D. E., Neuteboom, B., and Jusko, W. J. (2005) Pharmacokinetics and Pharmacodynamics of PEGylated IFN-β 1a Following Subcutaneous Administration in Monkeys. Pharm. Res. 22, 58-61.
45. Grace, M., Youngster, S., Gitlin, G., Sydor, W., Xie, L., Westreich, L., Jacobs, S., Brassard, D., Bausch, J., and Bordens, R. (2001) Structural and Biological Characterization of Pegylated Recombinant IFN-α2b. J. Interferon Cytokine Res. 21, 1103-1115.
46. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., Farid, A., Berthold, W., and Graves, M. (2001) Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon α-2a for the Treatment of Hepatitis C. Bioconjugate Chem. 12, 195-202.
47. Rosendahl, M. S., Doherty, D. H., Smith, D. J., Carlson, S. J., Chlipala, E. A., and Cox, G. N. (2005) A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific Mutagenesis. Bioconjugate Chem. 16, 200-207.
48. Piehler, J., and Schreiber, G. (1999) Mutational and Structural Analysis of the Binding Interface Between Type I Interferons and their Receptor Ifnar2. J. Mol. Biol. 294, 223-237.
49. Roisman, L. C., Piehler, J., Trosset, J.-Y., Scheraga, H. A., and Schreiber, G. (2001) Structure of the Interferon-Receptor Complex Determined by Distance Constraints from Double-Mutant and Flexible Docking. Proc. Natl. Acad. Sci. U.S.A. 98, 13231-13236.
50. Chill, J. H., Quadt, S. R., Levy, R., Schreiber, G., and Anglister, J. (2003) The Human Type I Interferon Receptor: NMR Structure Reveals the Molecular Basis of Ligand Binding. Structure 11, 791-802.
51. Panitch, H., Goodin, D. S., Francis, G., Chang, P., Coyle, P. K., O'Connor, P., Monaghan, E., Li, D. K. B., Weinshenker, B., for the EVIDENCE Study Group and the University of British Columbia MS/MRI Research Group (2002) Randomized, Comparative Study of Interferon β-1a Treatment Regimens in MS: The EVIDENCE Trial. Neurology 59, 1496-1506.
52. Lindner, D. J., and Borden, E. C. (1997) Synergistic Antitumor Effects of a Combination of Interferon and Tamoxifen on Estrogen Receptor-Positive and Receptor-Negative Human Tumor Cell Lines In Vivo and In Vitro. J. Interferon Cytokine Res. 17, 681-693.